Stock Market Reviews

NVCR (NovoCure Limited) News

Get the latest news, insights, and market updates on NVCR (NovoCure Limited). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Stocks to Watch Thursday Recap: Cisco, McDonald’s, AppLovin
  ↘️ Cisco Systems (CSCO): The networking-equipment company logged higher revenue due to increasing AI hyperscaler demand. Shares fell 12%, however, after a strong run for the stock so far in 2026. 🔎 McDonald's (MCD): The world’s largest burger chain reported stronger-than-expected growth in same-store sales and said its value campaign is paying off.
  Feb 12, 2026 - $NVCR
• These Stocks Are Today’s Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More
  AppLovin and Cisco slide after reporting earnings while Fastly soars on better-than-expected quarterly profit and solid guidance.
  Feb 12, 2026 - $NVCR
• Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift.
  The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.
  Feb 12, 2026 - $NVCR
• U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
  BAAR, Switzerland, February 11, 2026--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.
  Feb 11, 2026 - $NVCR
• Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
  The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax product.
  Feb 11, 2026 - $NVCR
• Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
  PRINCETON, N.J., January 20, 2026--Peter Melnyk joins Taiho Oncology as President & Chief Operating Officer.
  Jan 20, 2026 - $NVCR
• Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
  BAAR, Switzerland, January 12, 2026--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
  Jan 12, 2026 - $NVCR
• Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
  Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
  Jan 7, 2026 - $NVCR
• Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump?
  Wondering if NovoCure at around $13 is a beaten down bargain or just a value trap? Here is a look at what the numbers are quietly saying about where the stock stands today. Despite a brutal longer term slide, with the share price still down 55.2% year to date and 56.6% over the last year, the stock has shown some recent strength, gaining 9.0% in the last week and 7.3% over the past month. Those short term gains have come as investors refocus on NovoCure's Tumor Treating Fields technology and...
  Dec 25, 2025 - $NVCR
• NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows
  NovoCure (NVCR) has quietly bounced off its lows, with the stock up about 9% over the past week and roughly 7% over the past month, even as longer term returns remain deeply negative. See our latest analysis for NovoCure. At around $13.44 per share, NovoCure’s recent 7 day and 30 day share price returns suggest a tentative shift in sentiment, even though the year to date share price return and longer term total shareholder returns remain deeply negative, so momentum is stabilising rather than...
  Dec 25, 2025 - $NVCR